1. Home
  2. EDRY vs CELU Comparison

EDRY vs CELU Comparison

Compare EDRY & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EuroDry Ltd.

EDRY

EuroDry Ltd.

HOLD

Current Price

$16.25

Market Cap

38.7M

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.42

Market Cap

34.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDRY
CELU
Founded
2018
2016
Country
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.7M
34.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EDRY
CELU
Price
$16.25
$1.42
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
4.0K
31.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$19.70
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.60
$1.00
52 Week High
$16.14
$4.35

Technical Indicators

Market Signals
Indicator
EDRY
CELU
Relative Strength Index (RSI) 68.71 60.85
Support Level $13.64 $1.20
Resistance Level $14.85 $1.31
Average True Range (ATR) 0.68 0.09
MACD 0.16 0.02
Stochastic Oscillator 83.26 75.76

Price Performance

Historical Comparison
EDRY
CELU

About EDRY EuroDry Ltd.

EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: